EVUSHELD

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Estonia, Ireland, Japan, Lithuania, Poland, Romania.

Active ingredients

The drug EVUSHELD contains a combination of these active pharmaceutical ingredients (APIs):

1	Tixagevimab UNII F0LZ415Z3B - TIXAGEVIMAB
2	Cilgavimab UNII 1KUR4BN70F - CILGAVIMAB

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EVUSHELD Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BD03		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02526271
EE	Ravimiamet	1879926
JP	医薬品医療機器総合機構	62505A1A1028
LT	Valstybinė vaistų kontrolės tarnyba	1094411
PL	Rejestru Produktów Leczniczych	100466622
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68715001
US	FDA, National Drug Code	0310-1061, 0310-7442, 0310-8895